A Study to Evaluate SAGE-217 in Subjects With Moderate to Severe Major Depressive Disorder (Q66077325)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A Study to Evaluate SAGE-217 in Subjects With Moderate to Severe Major Depressive Disorder |
clinical trial |
Statements
A Phase 2, Two-Part (Open-Label Followed by Double-Blind) Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in the Treatment of Adult Subjects With Moderate to Severe Major Depressive Disorder (English)
0 references
7 December 2016
0 references
4 October 2017
0 references
102
0 references
18 year
0 references
65 year
0 references
1 reference